Omakase has presented at ISPOR 2022 in Vienna the following POSTER: “Do you want to know factors influencing Orphan PnR in Spain?”
The analysis has shown a clinical and regulatory variables that could be relevant for Pricing and Reimbursement (P&R) decisions for Orphan Drugs (OD) in Spain. the analysis has shown that ODs might be more likely to be reimbursed in Spain if they have a positive TPR conclusion (80% were reimbursed), if indicated for an ultra-rare disease (63% were reimbursed), if their clinical programme is based on survival-related outcomes (57% were reimbursed), if they are approved without conditional approval (55% were reimbursed) and if directed to an oncology indication (51% were reimbursed). Economic variables could not be assessed in this study because of lack of transparency in public sources.